Nintedanib and Weekly Docetaxel in Lung Adenocarcinoma

NCT02668393 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Docetaxel
DRUG: Nintedanib
DRUG: Nintedanib
DRUG: Nintedanib
DRUG: Nintedanib

Sponsor

Boehringer Ingelheim